Abstract 248P
Background
Over the past decade, a growing body of literature has elucidated the involvement of zinc homeostasis in tumor growth and progression. Herein, we present a bioinformatics-based study to evaluate the prognostic potential of zinc homeostasis-related genes in ccRCC.
Methods
The Human Genome Atlas Program (TCGA) was accessed to retrieve level 3 omics data and the corresponding clinicopathological variables. Differential expression of zinc homeostasis-related genes were considered statistically significant with a |Log2(fold change)| ≥ 1.5 and a P-value ≤ .01. The prognostic potential of selected genes was assessed using multivariate Cox logistic regression analysis. LinkedOmics was used to functionally annotate significantly co-expressed genes using KEGG terminology. Enrichment of the hallmarks of cancer gene sets was tested using gene set enrichment analysis (GSEA). Tumor immune microenvironment was explored using TIMER 2.0.
Results
A total of five significant differentially expressed genes were detected, including MT1G, SLC30A2, MT1F, SLC39A1, and MT1H. The latter being the only gene with a significant prognostic profile. High MT1H expression is associated with shortened overall survival (HR: 1.534, 95% CI: 1.140-2.064, P < .0048). Multivariate Cox logistic regression identified MT1H as an independent prognostic biomarker in ccRCC (HR: 1.392, 95% CI: 1.016-1.907, P < .04). MT1H co-expressed genes annotation highlighted the involvement of mineral absorption, ribosome, oxidative phosphorylation, and proteasome pathways. GSEA illustrated several alternations in epithelial-mesenchymal transition, inflammatory response,coagulation, complement, IL-6/JAK/STAT3 signaling, glycolysis, KRAS signaling, hypoxia, E2F targets, estrogen response, INF-γ signaling, and apoptosis. No clear trends or patterns were observed in tumor immune microenvironment in response to MT1H upregulation.
Conclusions
MT1H has been identified as a potential prognostic biomarker in ccRCC. Further experimental studies are needed to confirm the observed findings and to detect the exact molecular modulators involved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract